Vaseem Mahboob

This profile gathers the share dealings of Vaseem Mahboob across 3 companies, led by Endologix Inc /DE/, Kestra Medical Technologies, Ltd. and Insys Therapeutics, Inc. In total, 35 filings cover trades dated from 4 February 2016 to 7 August 2026.

In open-market terms, that means 3 purchases worth €270k on one side and 7 sales worth €1.1M on the other. The net balance comes to €833k on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 24 share grants. 2026 to date brings no purchases and 7 sales.

The median purchase comes to €89k. Clusters matter here: 2 out of 3 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

Most recently, on 11 August 2026, the filings show an open-market sale worth €579k in Kestra Medical Technologies, Ltd. The most recent open-market purchase was published on 3 April 2019, 2,758 days ago. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.